Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

Next Previous
Trial Profile

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QR-1123 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms AURORA
  • Sponsors ProQR Therapeutics

    • Most Recent Events

    • 10 Oct 2019 Status changed from planning to recruiting.
    • 09 Sep 2019 According to a ProQR Therapeutics media release, the company looks forward to beginning enrollment in the coming months.
    • 12 Aug 2019 According to a ProQR Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QR-1123. The company on this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top